reports
1 director sold
A director at Biodue sold 2,264,280 shares at 6.500EUR and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
- Lucia Saluzzi
Biodue S.p.a., Flash Note
BioDue S.p.A. develops, manufactures and markets cosmetics, solid and liquid food supplements and medical devices both on behalf of national and international pharmaceutical companies (Industrial division), both under its own brands (Pharcos, BiOfta and Selerbe). Biodue has announced that it has signed, on November 24th, binding agreements with Labiotre’ shareholders, Labomar (39% owned by Labiotre) and Previfarma (22% owned by Labiotre), to subscribe in December 2017 a 1M€ private capital incr...
- Lucia Saluzzi
Biodue S.p.a., 1H2017
BioDue S.p.A. develops, manufactures and markets cosmetics, solid and liquid food supplements and medical devices both on behalf of national and international pharmaceutical companies (Industrial division), both under its own brands (Pharcos, BiOfta and Selerbe). BioDue has adopted the IFRS accounting standards for the preparation of the financial statements as of January 1, 2017. In the 1H2017 BioDue’s turnover increased 3.3% yoy and amounted to 18.4M€ driven by Selerbe's excellent performanc...
- Lucia Saluzzi
Biodue S.p.a. FY2016
BioDue S.p.A. develops, manufactures and markets cosmetics, solid and liquid food supplements and medical devices both on behalf of national and international pharmaceutical companies (Industrial division), both under its own brands (Pharcos, BiOfta and Selerbe). In the FY2016 BioDue’s turnover increased 3.1% yoy and amounted to 34.8M€. The EBITDA (IAS principles) declined 1% yoy to 4.7M€ (13.6% EBITDA margin) and the net income amounted to 2.0M€, versus 2.4M€ of twelve months before.
- Lucia Saluzzi
Biodue S.p.a.
BioDue S.p.A. develops, manufactures and markets cosmetics, solid and liquid food supplements and medical devices both on behalf of national and international pharmaceutical companies (Industrial division), both under its own brands (Pharcos, BiOfta and Selerbe). Since May 20th 2015 BioDue is listed on the Italian Stock Exchange, AIM market. The IPO price was fixed equal to 3.55€ per share, they were issued 1.1 million new shares and the gross IPO proceeds amounted to 4M€.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.